{"disease":{"id":"progressive-multiple-sclerosis","name":"progressive multiple sclerosis"},"drugs":{"marketed":[{"drug_id":"ocrelizumab","indication_name":"Primary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocrevus","generic_name":"OCRELIZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"6500","mechanism":"Ocrevus works by binding to the CD20 protein on B cells, marking them for destruction and reducing their ability to contribute to the disease process."},{"drug_id":"humax-cd20","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"siponimod","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"mayzent","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ocrevus","indication_name":"Primary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ocrevus","company_name":"Kessler Foundation","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"arzerra","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03552211","title":"Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT06372145","title":"A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT01665144","title":"Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1651,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07225504","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04411641","title":"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1131,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT00731692","title":"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":970,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03387670","title":"Multiple Sclerosis-Simvastatin Trial 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":964,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03523858","title":"A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":927,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01416181","title":"A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":889,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT04458051","title":"Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":767,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05974839","title":"Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)","phase":"","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"State University of New York at Buffalo","has_results":false},{"nct_id":"NCT05974852","title":"Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS","phase":"","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"State University of New York at Buffalo","has_results":false},{"nct_id":"NCT07168694","title":"A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04688788","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04593927","title":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients","phase":"","overall_status":"COMPLETED","enrollment_count":451,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01910259","title":"MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":445,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT02284568","title":"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":374,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT05826028","title":"Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo","phase":"","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04940065","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","phase":"","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07282574","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06526000","title":"Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT05740722","title":"Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Haukeland University Hospital","has_results":false},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06320444","title":"Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"University of Dublin, Trinity College","has_results":false},{"nct_id":"NCT05232825","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06588387","title":"A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT04695080","title":"ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05961644","title":"Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Institute of Psychiatry and Neurology, Warsaw","has_results":false},{"nct_id":"NCT05663853","title":"An Observational Biomarker Study in Multiple Sclerosis (MS) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"LAPIX Therapeutics Inc.","has_results":false},{"nct_id":"NCT05376579","title":"Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy","phase":"","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03283826","title":"Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":134,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false},{"nct_id":"NCT05893225","title":"Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT05706220","title":"Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","has_results":false},{"nct_id":"NCT06395909","title":"A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT02988401","title":"Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT03302806","title":"Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05327322","title":"Functional Outcomes From Diets in Multiple Sclerosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT00950248","title":"Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT03315923","title":"Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Isfahan University of Medical Sciences","has_results":false},{"nct_id":"NCT06485115","title":"Telerehabilitation in Progressive Multiple Sclerosis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":78,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT04705610","title":"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Association de Recherche Bibliographique pour les Neurosciences","has_results":false},{"nct_id":"NCT07355387","title":"Home Based Functional Balance Intervention for Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT05359653","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03783416","title":"SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT02580669","title":"Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis","phase":"NA","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05685784","title":"Multiple Sclerosis Prediction and Monitoring of Progression Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT05496881","title":"Exercise Effects in Multiple Sclerosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"University of Regina","has_results":false},{"nct_id":"NCT02313285","title":"A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}